Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis.

ABSTRACT:

Introduction

Metastasis to the central nervous system (CNS) is frequently observed in human epidermal growth factor receptor (HER2)-positive breast cancer, leading to reduced quality of life and poor prognosis. Brain metastases (BMs) are common, whereas spinal cord metastases are rare and no standardized treatment approach has been reported for their management. Herein, we report the outcomes of treatment with trastuzumab deruxtecan (T-DXd) in a patient with BMs and intramedullary spinal cord metastasis (ISCM) and another patient with BMs.

Case presentation

The first patient was a woman in her 30s. After the surgery for HER2-positive right breast cancer, T-DXd was used as fourth-line treatment for multiple BMs and ISCM. Both the BMs and ISCM reduced, and partial response was

SUBMITTER: Yamane H 

PROVIDER: S-EPMC11666267 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature